JP2023055871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023055871A5 JP2023055871A5 JP2023014793A JP2023014793A JP2023055871A5 JP 2023055871 A5 JP2023055871 A5 JP 2023055871A5 JP 2023014793 A JP2023014793 A JP 2023014793A JP 2023014793 A JP2023014793 A JP 2023014793A JP 2023055871 A5 JP2023055871 A5 JP 2023055871A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- composition
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024189529A JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050948P | 2014-09-16 | 2014-09-16 | |
| US62/050,948 | 2014-09-16 | ||
| US201462067642P | 2014-10-23 | 2014-10-23 | |
| US62/067,642 | 2014-10-23 | ||
| US201462083929P | 2014-11-25 | 2014-11-25 | |
| US62/083,929 | 2014-11-25 | ||
| US201462093141P | 2014-12-17 | 2014-12-17 | |
| US201462093124P | 2014-12-17 | 2014-12-17 | |
| US62/093,141 | 2014-12-17 | ||
| US62/093,124 | 2014-12-17 | ||
| JP2020166883A JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020166883A Division JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024189529A Division JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023055871A JP2023055871A (ja) | 2023-04-18 |
| JP2023055871A5 true JP2023055871A5 (https=) | 2023-08-08 |
| JP7580506B2 JP7580506B2 (ja) | 2024-11-11 |
Family
ID=54105801
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514485A Pending JP2017538660A (ja) | 2014-09-16 | 2015-09-15 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2020166883A Pending JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2023014793A Active JP7580506B2 (ja) | 2014-09-16 | 2023-02-02 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2024189529A Pending JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514485A Pending JP2017538660A (ja) | 2014-09-16 | 2015-09-15 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2020166883A Pending JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024189529A Pending JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10676523B2 (https=) |
| EP (1) | EP3193929B1 (https=) |
| JP (4) | JP2017538660A (https=) |
| KR (2) | KR20240141862A (https=) |
| CN (1) | CN107074950A (https=) |
| AU (3) | AU2015316993B2 (https=) |
| CA (1) | CA2959463A1 (https=) |
| DK (1) | DK3193929T3 (https=) |
| ES (1) | ES2742456T3 (https=) |
| HU (1) | HUE044704T2 (https=) |
| IL (1) | IL250672B (https=) |
| PL (1) | PL3193929T3 (https=) |
| SG (2) | SG10202007781TA (https=) |
| WO (1) | WO2016041947A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| KR102047248B1 (ko) | 2011-06-17 | 2019-11-21 | 노보 노르디스크 에이/에스 | 침식성 세포의 선택적 제거 |
| SMT202000562T1 (it) | 2014-09-16 | 2020-11-10 | Innate Pharma | Neutralizzazionne delle vie inibitorie nei linfociti |
| CA2959463A1 (en) | 2014-09-16 | 2016-03-24 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| AU2016299166B2 (en) | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| CA3012055A1 (en) | 2016-01-21 | 2017-07-27 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US20190248895A1 (en) | 2016-10-21 | 2019-08-15 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| AU2018298673A1 (en) | 2017-07-10 | 2019-12-19 | Innate Pharma | Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| EA202092147A1 (ru) * | 2018-03-13 | 2021-03-04 | Иннейт Фарма | Лечение рака головы и шеи |
| PE20210665A1 (es) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | Anticuerpos contra mica y/o micb y sus usos |
| EP3793607A1 (en) | 2018-05-15 | 2021-03-24 | MedImmune Limited | Treatment of cancer |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| EP3878869A4 (en) * | 2018-11-07 | 2023-04-19 | Shanghai Hyamab Biotech Co., Ltd. | NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF |
| US11274150B2 (en) | 2018-11-16 | 2022-03-15 | Bristol-Myers Squibb Company | Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies |
| SG11202110579WA (en) * | 2019-03-29 | 2021-10-28 | Dren Bio Inc | Methods of reducing large granular lymphocyte and natural killer cell levels |
| JP2022534967A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
| EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| EP4054591A1 (en) | 2019-11-04 | 2022-09-14 | Astrazeneca AB | Combination therapy for treating cancer |
| CN113583127A (zh) * | 2020-04-30 | 2021-11-02 | 迈威(上海)生物科技股份有限公司 | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| US20230348854A1 (en) * | 2020-05-08 | 2023-11-02 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Chimeric antigen receptors (cars) targeting natural killer cells |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022072508A1 (en) | 2020-09-30 | 2022-04-07 | Dren Bio, Inc. | Anti-cd94 antibodies and methods of use thereof |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| SMT202500208T1 (it) | 2020-12-28 | 2025-07-22 | Bristol Myers Squibb Co | Composizioni anticorpali e metodi per il loro uso |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| CA3222040A1 (en) | 2021-06-01 | 2022-12-08 | Les Laboratoires Servier | Anti-nkg2a antibodies and compositions |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| EP4493575A1 (en) | 2022-03-18 | 2025-01-22 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| EP4531916A1 (en) | 2022-06-02 | 2025-04-09 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| KR20250120305A (ko) | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| WO2024150017A1 (en) | 2023-01-13 | 2024-07-18 | Akrivia Biomedics Limited | Method of profiling diseases |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| CN121712571A (zh) | 2023-08-15 | 2026-03-20 | 百时美施贵宝公司 | 陶瓷羟基磷灰石色谱流通法 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| NL2037811B1 (en) | 2024-05-29 | 2025-12-12 | Univ Oslo | Treatment for Cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| US20030095965A1 (en) | 2001-05-02 | 2003-05-22 | Katrien Van Beneden | Antibodies to Ly49E and CD94/NKG2 receptors |
| CN101107269B (zh) * | 2004-12-28 | 2012-10-31 | 依奈特制药公司 | 抗nkg2a的单克隆抗体 |
| AU2005321017B2 (en) * | 2004-12-28 | 2011-02-24 | Innate Pharma S.A. | Monoclonal antibodies against NKG2A |
| CN101484471B (zh) | 2006-06-30 | 2013-11-06 | 诺沃-诺迪斯克有限公司 | 抗-nkg2a抗体及其用途 |
| EP2628753A1 (en) | 2008-01-24 | 2013-08-21 | Novo Nordisk A/S | Humanized anti-human NKG2A monoclonal antibody |
| US20110033389A1 (en) | 2009-04-29 | 2011-02-10 | Zhifeng Chen | Modified antibodies for passive immunotherapy |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| KR102047248B1 (ko) * | 2011-06-17 | 2019-11-21 | 노보 노르디스크 에이/에스 | 침식성 세포의 선택적 제거 |
| JP2017533255A (ja) | 2014-08-28 | 2017-11-09 | アカデミス・ジーケンハイス・ライデン・ハー・オー・デー・エヌ・エルユーエムセーＡｃａｄｅｍｉｓｃｈ Ｚｉｅｋｅｎｈｕｉｓ Ｌｅｉｄｅｎ Ｈ．Ｏ．Ｄ．Ｎ． Ｌｕｍｃ | Ｃｄ９４／ｎｋｇ２ａおよび／またはｃｄ９４／ｎｋｇ２ｂ抗体、ワクチンの組み合わせ |
| SMT202000562T1 (it) | 2014-09-16 | 2020-11-10 | Innate Pharma | Neutralizzazionne delle vie inibitorie nei linfociti |
| CA2959463A1 (en) | 2014-09-16 | 2016-03-24 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| CA3012055A1 (en) | 2016-01-21 | 2017-07-27 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| EA202092147A1 (ru) | 2018-03-13 | 2021-03-04 | Иннейт Фарма | Лечение рака головы и шеи |
| EP3793607A1 (en) | 2018-05-15 | 2021-03-24 | MedImmune Limited | Treatment of cancer |
-
2015
- 2015-09-15 CA CA2959463A patent/CA2959463A1/en active Pending
- 2015-09-15 KR KR1020247031251A patent/KR20240141862A/ko active Pending
- 2015-09-15 ES ES15763016T patent/ES2742456T3/es active Active
- 2015-09-15 KR KR1020177008837A patent/KR20170068458A/ko not_active Ceased
- 2015-09-15 SG SG10202007781TA patent/SG10202007781TA/en unknown
- 2015-09-15 HU HUE15763016 patent/HUE044704T2/hu unknown
- 2015-09-15 SG SG11201701387SA patent/SG11201701387SA/en unknown
- 2015-09-15 CN CN201580050103.1A patent/CN107074950A/zh active Pending
- 2015-09-15 WO PCT/EP2015/071073 patent/WO2016041947A1/en not_active Ceased
- 2015-09-15 DK DK15763016.1T patent/DK3193929T3/da active
- 2015-09-15 JP JP2017514485A patent/JP2017538660A/ja active Pending
- 2015-09-15 AU AU2015316993A patent/AU2015316993B2/en active Active
- 2015-09-15 PL PL15763016T patent/PL3193929T3/pl unknown
- 2015-09-15 EP EP15763016.1A patent/EP3193929B1/en active Active
- 2015-09-15 US US15/511,792 patent/US10676523B2/en active Active
-
2017
- 2017-02-19 IL IL250672A patent/IL250672B/en active IP Right Grant
-
2020
- 2020-06-08 US US16/894,937 patent/US20200299383A1/en not_active Abandoned
- 2020-10-01 JP JP2020166883A patent/JP2021008487A/ja active Pending
-
2021
- 2021-04-08 US US17/225,160 patent/US12037392B2/en active Active
- 2021-06-07 AU AU2021203744A patent/AU2021203744B2/en active Active
-
2023
- 2023-02-02 JP JP2023014793A patent/JP7580506B2/ja active Active
-
2024
- 2024-07-15 US US18/772,517 patent/US20240368281A1/en active Pending
- 2024-10-29 JP JP2024189529A patent/JP2025016606A/ja active Pending
-
2025
- 2025-07-17 AU AU2025205563A patent/AU2025205563A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023055871A5 (https=) | ||
| JP2025016606A5 (https=) | ||
| KR101905208B1 (ko) | Cd38을 특이적으로 인식하는 항체 및 보르테조밉을 함유하는 항종양 조합물 | |
| TWI436770B (zh) | 包含專一性辨識ｃｄ３８之抗體及阿糖胞苷（ｃｙｔａｒａｂｉｎｅ）之抗腫瘤組合 | |
| JP6215429B2 (ja) | Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ | |
| TWI454260B (zh) | 包含專一性辨識ｃｄ３８之抗體及黴法蘭（ｍｅｌｐｈａｌａｎ）之抗腫瘤組合 | |
| KR101733253B1 (ko) | Ｃｄ３８을 특이적으로 인식하는 항체 및 빈크리스틴을 함유하는 항종양 조합물 | |
| JP2009518441A5 (https=) | ||
| CN105407921A (zh) | 包含抗cd38抗体和卡非佐米的组合物 | |
| JP2021512107A5 (https=) | ||
| HK1164152A (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine | |
| HK1185022A (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib | |
| HK1185022B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib | |
| HK1164165B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan | |
| JPWO2021038097A5 (https=) |